MxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-α

Journal of Medical Virology

Volumn 62, Issue 3, 2000, Pages 318-326

  Meier, V ^a   Mihm, S ^a   Ramadori, G ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Beta 2 microglobulin; Hepatitis C virus; Interferon ; MxA

Indexed keywords

BETA 2 MICROGLOBULIN; PROTEIN; RECOMBINANT ALPHA2A INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRUS HEPATITIS;

ADULT; BETA 2-MICROGLOBULIN; FEMALE; GTP-BINDING PROTEINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, VIRAL;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0033804119     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9071(200011)62:3<318::AID-JMV3>3.0.CO;2-2     Document Type: Article

References (59)

1. cDNA structures and regulation of two interferon-induced Mx proteins
2. Interferon α-2b as therapy for Ph'-positive chronic myelogenous leukemia: A study of 82 patients treated with intermittent or daily administration
3. Mechanism of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis
4. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-α therapy
5. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g
6. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients
7. The MxA protein levels in whole blood lysates of patients with various viral infections
8. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
9. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
10. Analysis of interferon-inducible genes in cells of chronic myeloid leukemia patients responsive or resistant to an interferon-α treatment
11. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial
12. Involvement of the double-stranded-RNA-dependent kinase PKR in interferon expression and interferon-mediated antiviral activity
13. Classification of chronic hepatitis: Diagnosis, grading and staging
14. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
15. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region
16. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
17. In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus
18. Inhibition of bunyaviruses, phleboviruses, and hantaviruses by human MxA protein
19. Effectiveness of interferon-α therapy in chronic hepatitis C is associated with the amount of interferon-α receptor mRNA in the liver
20. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
21. Ribonucleic acid isolated by cesium chloride centrifugation
22. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy
23. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-α therapy
24. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses
25. Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C
26. Comparison of two interferon alpha treatment regimens characterized by an early virological response in patients with chronic hepatitis C
27. Pilot study of recombinant human alpha-interferon for chronic non-A, non-B hepatitis
28. IRF-1 induced cell growth inhibition and interferon induction requires the activity of the protein kinase PKR
29. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
30. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA
31. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
32. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha
33. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C
34. Therapy of hepatitis C: Overview
35. Interferon-α treatment in patients with chronic hepatitis C: A meta-analytic evaluation
36. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution
37. Activity of rat Mx proteins against a rhabdovirus
38. Preferential virological response to interferon-α2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low gamma-GT/ALT ratio
39. High inflammatory activity is associated with an increased amount of IFN-γ transcripts in peripheral blood cells of patients with chronic hepatitis C virus infection
40. Lack of clinical evidence for involvement of hepatitis C ISDR variability in PKR-mediated cellular antiviral response
41. Cytokines in the control of beta-2 microglobulin release. I. In vitro studies on various haemopoietic cells
42. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy
43. Activity of the interferon-induced 2',5'-oligoadenylate synthetase in patients with chronic hepatitis C
44. Effect of alpha interferon (IFN-α) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: Relationship to the antiviral effect of IFN-α
45. Interferons and their actions
46. A functional GTP-binding motif is necessary for antiviral activity of Mx proteins
47. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C and their relation to therapeutic response to interferon-α
48. 2-microglobulin by hepatocytes
49. Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
50. MxA gene expression after live virus vaccination: A sensitive marker for endogenous type I interferon
51. Control of IFN-inducible MxA gene expression in human cells
52. Mechanisms of the antiviral action of interferons
53. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities
54. Interferon-induced antiviral actions and their regulation
55. Interferon-induced proteins and the antiviral state
56. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia
57. Early HCV RNA values after interferon predict response
58. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alpha on viral turnover
59. Inhibition of human parainfluenza virus-3 replication by interferon and human MxA